UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.
In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.
Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”
Eli Lilly & Co. closed on Tuesday at $52.80.
Latest Ratings for LLY
|Jun 2015||Leerink Swann||Maintains||Outperform|
|Jun 2015||Bank of America||Upgrades||Neutral||Buy|
|Jun 2015||Argus Research||Maintains||Buy|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.